Ticker: ABBOTINDIA.NS

Compañia: Abbott India Limited

Índice: NSI

Sector: Salud

Divisa: EURINR

Valor actual: 16819.85

Descripción:

Noticias de  ABBOTINDIA.NS

Abbott India Limited opera como empresa farmacéutica en India. Ofrece productos farmacéuticos para diversas áreas terapéuticas, como la salud de la mujer, gastroenterología, metabolismo, sistema nervioso central, manejo del dolor, suplementos nutricionales, vitaminas, insomnio, vacunas, salud del consumidor, etc. La empresa se conocía anteriormente como Knoll Pharmaceuticals Limited y cambió su nombre a Abbott India Limited en julio de 2002. Abbott India Limited se incorporó en 1944 y tiene su sede en Mumbai, India. Abbott India Limited es una subsidiaria de Abbott Capital India Limited.

Noticias:

Noticias de  ABBOTINDIA.NS

enoxaparina Mercado 2022 (análisis de COVID-19): informe de análisis de participación, crecimiento y tendencias de ...

El mercado global enoxaparina extrapola las tendencias del mercado, las acciones, los ingresos y el tamaño. Nuestro informe sobre investigación de mercado...

Política para ti | Política para ti

Noticias de  ABBOTINDIA.NS

Etexilato de dabigatrán Mercado 2022 | Análisis global de la industria por tendencias, tamaño, participación, descripción general de la empresa, crecimiento y pronóstico para 2025 | Informe de investigación más reciente

Etexilato de dabigatrán Mercado (2022-2025) informe de investigación representa una visión detallada de la situación actual del mercado y las previsiones...

La Vanguardia Noticias | La Vanguardia Noticias

Noticias de  ABBOTINDIA.NS

Abbott India Ltd up for five straight sessions

Abbott India Ltd is quoting at Rs 19495.95, up 0.59% on the day as on 12:49 IST on the NSE. The stock is up 23.82% in last one year as compared to a 24.07%...

Business Standard | Business Standard

Noticias de  ABBOTINDIA.NS

“BUY” This Large Cap Pharma Stock With A Target Price of Rs. 22,780: Sharekhan

In a time where pharma stocks are gaining traction, Sharekhan Ltd has issued a buy recommendation on Abbott India Ltds stock. From its current market price...

Goodreturns | Goodreturns

Noticias de  ABBOTINDIA.NS

Genpharmasec commences first direct order with Abbott Point of Care; Stock dips over 4%

In May this year, Genpharmasec had entered into a landmark Distribution Agreement with Abbott Point of Care (APOC) for selling their niche diagnostic...

IndiaInfoline | IndiaInfoline

Noticias de  ABBOTINDIA.NS

Traders Dairy: From cash to F&O, Zee Business analysts recommend these stocks for good returns

In a Trader's Dairy segment, Zee Business Research Analysts Varun Dubey and Ashish Chaturvedi suggest some stocks from the cash, F&O markets.

Zee Business | Zee Business

Noticias de  ABBOTINDIA.NS

Sharekhan maintains 'buy' on these 15 pharma names post Q2 earnings. Take a look

Cadila Healthcare, Dr Reddy's and Sun Pharma among the preferred largecap picks of Sharekhan. Read on to know which stocks Sharekhan is backing and why.

Moneycontrol | Moneycontrol

Noticias de  ABBOTINDIA.NS

Nifty forms bullish candle. What does it signals about Monday's trade?

The Dow Jones Industrial Average rose 42.55 points, or 0.12%, at the open to 35,963.78. The S&P 500 opened higher by 5.97 points, or 0.13%, at 4,655.24,...

The Economic Times | The Economic Times

Noticias de  ABBOTINDIA.NS

Stock Market Highlights: Sensex ends 767 points higher, Nifty50 reclaims 18,100 as market breaks 3-day losing

Stock Market Highlights: Indian equity benchmarks Sensex and Nifty50 rebounded on Friday, snapping a losing streak that stretched to three days in a row.

CNBC TV18 | CNBC TV18

Noticias de  ABBOTINDIA.NS

Abbott India Q2FY22 Result: Net profit up 6% to Rs 192 crore

The company had posted a net profit of Rs 180.73 crore in the corresponding period of the previous fiscal. Get more Companies News and Business News on Zee...

Zee Business | Zee Business

Noticias de  ABBOTINDIA.NS

Do Abbott India's (NSE:ABBOTINDIA) Earnings Warrant Your Attention?

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks with a good story, even if those...

Simply Wall St | Simply Wall St